La thérapie par cellules souches montre son efficacité dans le traitement du COVID-19, trouve une étude

Researchers in China administered COVID-19 patients with a mesenchymal stem cell therapy that demonstrated success at treating the condition.

Blue stem cells
A group of researchers has used a stem cell treatment on a patient in Beijing, China to effectively boost the immune system to fight the COVID-19 coronavirus.

“A lot of people are trying find the answers,” said scientist that led the research

He said that early findings are promising and the international effort to test this treatment continues as a long-term study with more patients in China.

 

“Our study showed that intravenous infusion of clinical-grade human mesenchymal stem cells is a safe and efficient approach for treating patients with COVID-19 pneumonia, including in elderly patients displaying severe pneumonia,» .

The stem cells were injected intravenously into the bloodstream of seven patients in YouAn Hospital in Beijing who were severely ill, while three patients were injected with a placebo.

The seven patients who received stem cells were successfully treated and discharged from the hospital within 14 jours, report the researchers. Of the patients who received the placebo, one died, one became severe and the third had Acute Respiratory Distress Syndrome (SDRA).

“No specific drugs or vaccines are available to cure the patients with COVID-19 infection,” write the authors of the study. “Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the severe cases.”

The findings are published in Aging and Disease.

Consultant en recherche scientifique

Vous souhaitez savoir si les programmes cliniques actuels, développements de la recherche, ou des approches thérapeutiques émergentes peuvent être pertinentes à votre situation?

Informations pédagogiques et de recherche uniquement. Les décisions médicales individuelles doivent être prises en consultation avec des professionnels de santé qualifiés..


NBScience

organisme de recherche sous contrat

WhatsApp